These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34829513)

  • 41. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
    Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
    Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
    Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
    Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
    Itchins M; Arena J; Nahm CB; Rabindran J; Kim S; Gibbs E; Bergamin S; Chua TC; Gill AJ; Maher R; Diakos C; Wong M; Mittal A; Hruby G; Kneebone A; Pavlakis N; Samra J; Clarke S
    Eur J Surg Oncol; 2017 Sep; 43(9):1711-1717. PubMed ID: 28688722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolving pancreatic cancer treatment: From diagnosis to healthcare management.
    Milella M; Bassi C; Boggi U; Brunetti O; Cavaliere A; Crippa S; De Vita F; Falconi M; Frassineti GL; Giommoni E; Macchini M; Malleo G; Silvestris N; Tudisco A; Vasile E; Reni M
    Crit Rev Oncol Hematol; 2022 Jan; 169():103571. PubMed ID: 34923121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MRI vs. CT for pancreatic adenocarcinoma vascular invasion: comparative diagnostic test accuracy systematic review and meta-analysis.
    Jajodia A; Wang A; Alabousi M; Wilks C; Kulkarni A; van der Pol CB
    Eur Radiol; 2023 Oct; 33(10):6883-6891. PubMed ID: 37083741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
    Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
    Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Bonds M; Rocha FG
    J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31409042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning.
    Zaky AM; Wolfgang CL; Weiss MJ; Javed AA; Fishman EK; Zaheer A
    Radiographics; 2017; 37(1):93-112. PubMed ID: 27885893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study.
    Vitolo V; Cobianchi L; Brugnatelli S; Barcellini A; Peloso A; Facoetti A; Vanoli A; Delfanti S; Preda L; Molinelli S; Klersy C; Fossati P; Orecchia R; Valvo F
    BMC Cancer; 2019 Sep; 19(1):922. PubMed ID: 31521134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review.
    Kwaśniewska D; Fudalej M; Nurzyński P; Badowska-Kozakiewicz A; Czerw A; Cipora E; Sygit K; Bandurska E; Deptała A
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.
    van Dam MA; Vuijk FA; Stibbe JA; Houvast RD; Luelmo SAC; Crobach S; Shahbazi Feshtali S; de Geus-Oei LF; Bonsing BA; Sier CFM; Kuppen PJK; Swijnenburg RJ; Windhorst AD; Burggraaf J; Vahrmeijer AL; Mieog JSD
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives.
    Coppola A; La Vaccara V; Farolfi T; Fiore M; Cammarata R; Ramella S; Coppola R; Caputo D
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.